Edaravone is a synthetic free-radical scavenger developed to reduce oxidative stress–related cellular damage. It works by neutralizing reactive oxygen species that contribute to neuronal injury. Edaravone was first approved in Japan for the treatment of acute ischemic stroke. Later, it gained global recognition for its role in managing amyotrophic lateral sclerosis (ALS). In ALS, it helps slow functional decline by protecting motor neurons from oxidative damage. The drug is administered intravenously and, in some regions, also available in oral formulations. Edaravone does not cure neurological disorders but helps delay disease progression. It is mainly used in hospital or specialty care settings under medical supervision. Ongoing research continues to explore its broader neuroprotective potential. Overall, Edaravone plays an important supportive role in neurological disease management.
